Guidance
Supplementary information on baseline investigations and monitoring
Supplementary information on baseline investigations and monitoring
- | Baseline investigations before starting antipsychotic medication | Monitor weekly for the first 6 weeks | Monitor at 12 weeks | Monitor every 6 months thereafter | Monitor regularly throughout treatment, and especially during titration |
---|---|---|---|---|---|
Weight (plotted on a growth chart) Calculate and document BMI (percentile). |
Yes |
Yes |
Yes |
Yes |
- |
Height (plotted on a growth chart) Calculate and document BMI (percentile). |
Yes |
- |
- |
Yes |
- |
Waist circumference (plotted on a percentile chart) |
Yes |
- |
- |
Yes |
- |
Pulse |
Yes |
- |
Yes |
Yes |
- |
Blood pressure (plotted on a percentile chart) |
Yes |
- |
Yes |
Yes |
- |
Fasting blood glucose or HbA1c (glycosylated haemoglobin) |
Yes |
- |
Yes |
Yes |
- |
Blood lipid profile |
Yes |
- |
Yes |
Yes |
- |
Prolactin level |
Yes |
- |
Yes |
Yes |
- |
Movement disorders (extrapyramidal symptoms, akathisia, dystonia and tardive dyskinesia) |
Yes |
- |
- |
- |
Yes Even if no baseline assessment (and at each clinic visit if more frequent) |
Nutritional status, diet and level of physical activity |
Yes |
- |
- |
- |
Yes |
The side effects the child or young person is most or least willing to tolerate |
Yes |
- |
- |
- |
- |
ECG |
Yes If specified in the SPC for adults and/or children; a physical examination has identified specific cardiovascular risk (such as diagnosis of high blood pressure); there is personal history of cardiovascular disease; there is a family history of cardiovascular disease such as sudden cardiac death or prolonged QT interval; or the child or young person is being admitted as an inpatient. |
- |
- |
- |
- |
Efficacy |
- |
- |
- |
- |
Yes |
Side effects |
- |
- |
- |
- |
Yes |
Adherence |
- |
- |
- |
- |
Yes |